Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

Efficacy and safety evaluation of sucrose-formulated recombinant factor VIII for Taiwanese patients with haemophilia A.

• J-H Young, H-c Liu, +5 authors Kirsten Achilles
• Haemophilia : the official journal of the World…
• 2009

J.-H. YOUNG,* H.-C. LIU, E.-J. HSUEH, M.-L. HUANG,§ C.-T. PENG,– R.-L. CHEN,** M. MAAS-ENRIQUEZ and K. ACHILLES *Lin Shin Hospital, Taichung, Taiwan; Mackay Memorial Hospital, Taipei, Taiwan;… (More)

Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.

• Roberto Musso, Elena Santagostino, +6 authors Eduard Gorina
• Thrombosis and haemostasis
• 2008

The safety of full-length sucrose-formulated recombinant factor VIII (rFVIII-FS; Kogenate FS) for up to 24 months of use was evaluated in a postmarketing observational study in Europe. Long-term… (More)

Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis--results of a retrospective multicenter observational study over five years.

• Jennifer S. Haas, Monika Maas-Enriquez, H. - P. Hartung
• Multiple sclerosis
• 2005

Use of intravenous immunoglobulins (IVIG) has been recommended for treatment of RRMS if first line therapy with beta-interferon or glatiramer acetate is not tolerated, or if contraindications exist.… (More)

No effect of intravenous immunoglobulins on cytokine-producing lymphocytes in secondary progressive multiple sclerosis.

• H. F. Petereit, Dean Reske, +8 authors Otto Roelf Hommes
• Multiple sclerosis
• 2006

Intravenous immunoglobulins (IVIG) have been effective in reducing multiple sclerosis (MS) disease activity and improving disability scores. However, the mechanism by which this beneficial effect is… (More)

ESIMS--an ongoing clinical trial in secondary progressive multiple sclerosis.

• Otto Roelf Hommes, Monika Maas-Enriquez
• Multiple sclerosis
• 2000

The design of a double-blind, placebo-controlled, European-Canadian Study on IVIG treatment in multiple sclerosis-ESIMS- is described. Three hundred and eighteen multiple sclerosis patients with a… (More)

[Anti-rubella IgM and IgG antibodies in congenital cardiopathy].

• Monika Maas-Enriquez, J Ovseyevitz, Patricia Reyes, Fause Attié
• Archivos del Instituto de Cardiologia de Mexico
• 1985

In utero infection by rubella virus is a well known cause of congenital heart disease. We look for prevalence of anti-rubella antibodies of IgM (primary response) or IgG (anamnestic response) classes… (More)

Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.

• Franz Fazekas, Fred D. Lublin, +7 authors K. Hanna
• Neurology
• 2008

OBJECTIVE Several studies have reported a reduction of relapses after the long-term administration of IV immunoglobulin (IVIG) to patients with relapsing-remitting multiple sclerosis (RRMS), but they… (More)

• ‹
• 1
• ›